Neuberger Berman Group LLC T Scan Therapeutics, Inc. Transaction History
Neuberger Berman Group LLC
- $124 Billion
- Q2 2025
A detailed history of Neuberger Berman Group LLC transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Neuberger Berman Group LLC holds 21,167 shares of TCRX stock, worth $41,487. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,167
Previous 21,167
-0.0%
Holding current value
$41,487
Previous $30,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding TCRX
# of Institutions
80Shares Held
37.7MCall Options Held
0Put Options Held
0-
Lynx1 Capital Management LP San Juan, PR7.86MShares$15.4 Million3.37% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$10.2 Million0.3% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$8.75 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY2.78MShares$5.46 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.15MShares$4.21 Million0.0% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $37.1M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...